MNKD logo

MannKind Corporation (MNKD)

$4.07

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MNKD

Market cap

$1.31B

EPS

-0.23

P/E ratio

--

Price to sales

2.69

Dividend yield

--

Beta

1.092601

Price on MNKD

Previous close

$3.96

Today's open

$3.96

Day's range

$3.90 - $4.18

52 week range

$2.23 - $6.51

Profile about MNKD

CEO

Michael E. Castagna

Employees

592

Headquarters

Danbury, CT

Exchange

NASDAQ Global Market

Shares outstanding

321640118

Issue type

Common Stock

MNKD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MNKD

MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations

MannKind NASDAQ: MNKD is focusing on the launch of its FUROSCIX ReadyFlow autoinjector, pediatric AFREZZA and the development of inhaled nintedanib, CEO Michael Castagna said at the UBS Biopharma Conference in London.

news source

MarketBeat • 14 hours ago

news preview

MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction

MannKind NASDAQ: MNKD expects to be profitable and report record revenue in the fourth quarter as it builds on the launch of FUROSCIX ReadyFlow and the pediatric approval of inhaled insulin Afrezza, CEO Michael Castagna said at the Jefferies 2026 Global Healthcare Conference.

news source

MarketBeat • 7 hours ago

news preview

MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript

MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

MannKind's ReadyFlow Launch Keeps The Bull Case Alive

MNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main caveat to this is that it requires an added lung-function screening for patients. Aside from that, Tyvaso DPI royalties remain vital for MNKD, but fortunately, they're likely to keep growing as well in the near term.

news source

Seeking Alpha • Nov 12, 2026

news preview

MannKind to Participate in Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

news source

GlobeNewsWire • Nov 10, 2026

news preview

MannKind Q3 Earnings Call Highlights

MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.

news source

MarketBeat • Nov 6, 2026

news preview

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Nov 6, 2026

news preview

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.

news source

GlobeNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MannKind Corporation

Open an M1 investment account to buy and sell MannKind Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MNKD on M1